Literature DB >> 21994366

The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.

Xin Wang1, Ana Sirianni, Zhijuan Pei, Kerry Cormier, Karen Smith, Jiying Jiang, Shuanhu Zhou, Hui Wang, Rong Zhao, Hiroko Yano, Jeong Eun Kim, Wei Li, Bruce S Kristal, Robert J Ferrante, Robert M Friedlander.   

Abstract

Melatonin mediates neuroprotection in several experimental models of neurodegeneration. It is not yet known, however, whether melatonin provides neuroprotection in genetic models of Huntington's disease (HD). We report that melatonin delays disease onset and mortality in a transgenic mouse model of HD. Moreover, mutant huntingtin (htt)-mediated toxicity in cells, mice, and humans is associated with loss of the type 1 melatonin receptor (MT1). We observe high levels of MT1 receptor in mitochondria from the brains of wild-type mice but much less in brains from HD mice. Moreover, we demonstrate that melatonin inhibits mutant htt-induced caspase activation and preserves MT1 receptor expression. This observation is critical, because melatonin-mediated protection is dependent on the presence and activation of the MT1 receptor. In summary, we delineate a pathologic process whereby mutant htt-induced loss of the mitochondrial MT1 receptor enhances neuronal vulnerability and potentially accelerates the neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994366      PMCID: PMC3213696          DOI: 10.1523/JNEUROSCI.3059-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  67 in total

1.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

2.  Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.

Authors:  Edward C Stack; Karen M Smith; Hoon Ryu; Kerry Cormier; Minghua Chen; Sean W Hagerty; Steven J Del Signore; Merit E Cudkowicz; Robert M Friedlander; Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2005-12-05

3.  Melatonin reduces quinolinic acid-induced lipid peroxidation in rat brain homogenate.

Authors:  G Southgate; S Daya
Journal:  Metab Brain Dis       Date:  1999-09       Impact factor: 3.584

4.  Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats.

Authors:  D Ozdemir; N Uysal; S Gonenc; O Acikgoz; A Sonmez; A Topcu; N Ozdemir; M Duman; I Semin; H Ozkan
Journal:  Physiol Res       Date:  2005       Impact factor: 1.881

5.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

6.  Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Madhur Gupta; Satinder Aneja; Kamlesh Kohli
Journal:  Epilepsy Behav       Date:  2004-06       Impact factor: 2.937

7.  Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescence-accelerated mice.

Authors:  Beatriz Caballero; Ignacio Vega-Naredo; Verónica Sierra; Covadonga Huidobro-Fernández; Clara Soria-Valles; David De Gonzalo-Calvo; Delio Tolivia; Javier Gutierrez-Cuesta; Merce Pallas; Antonio Camins; María Josefa Rodríguez-Colunga; Ana Coto-Montes
Journal:  J Pineal Res       Date:  2008-04-13       Impact factor: 13.007

8.  Influence of pinealectomy on plasma and extrapineal melatonin rhythms in young chickens (Gallus domesticus).

Authors:  L A Cogburn; S Wilson-Placentra; L R Letcher
Journal:  Gen Comp Endocrinol       Date:  1987-12       Impact factor: 2.822

9.  Effect of chronic consumption of sodium valproate and melatonin on seizure activity in Krushinskii-Molodkina rats.

Authors:  T A Savina; O A Balashova; T G Shchipakina
Journal:  Bull Exp Biol Med       Date:  2006-11       Impact factor: 0.804

10.  Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers.

Authors:  Lennard P Niles; Kristen J Armstrong; Lyda M Rincón Castro; Chung V Dao; Rohita Sharma; Catherine R McMillan; Laurie C Doering; David L Kirkham
Journal:  BMC Neurosci       Date:  2004-10-28       Impact factor: 3.288

View more
  53 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 3.  Melatonin receptors: molecular pharmacology and signalling in the context of system bias.

Authors:  Erika Cecon; Atsuro Oishi; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

4.  Silibinin Prevents Autophagic Cell Death upon Oxidative Stress in Cortical Neurons and Cerebral Ischemia-Reperfusion Injury.

Authors:  Min Wang; Yu-Jiao Li; Yi Ding; Hui-Nan Zhang; Ting Sun; Kun Zhang; Le Yang; Yan-Yan Guo; Shui-Bing Liu; Ming-Gao Zhao; Yu-Mei Wu
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 5.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 6.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 7.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

Review 8.  Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas.

Authors:  Russel J Reiter; Sergio Rosales-Corral; Dun Xian Tan; Mei Jie Jou; Annia Galano; Bing Xu
Journal:  Cell Mol Life Sci       Date:  2017-09-01       Impact factor: 9.261

9.  N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury.

Authors:  Hua Zhou; Jian Wang; Jiying Jiang; Irina G Stavrovskaya; Mingchang Li; Wei Li; Qiaofeng Wu; Xinmu Zhang; Chengliang Luo; Shuanhu Zhou; Ana C Sirianni; Sovan Sarkar; Bruce S Kristal; Robert M Friedlander; Xin Wang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

10.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.